WHO 2025年全球结核病报告：全球与中国关键数据分析

doi:10.19871/j.cnki.xfcrbzz.2025.06.001

新发传染病电子杂志 ›› 2025, Vol. 10 ›› Issue (6): 1-9.doi: 10.19871/j.cnki.xfcrbzz.2025.06.001

• WHO结核病报告和指南解读 • 下一篇

WHO 2025年全球结核病报告：全球与中国关键数据分析

何华伟¹, 黄爱春¹, 李纬¹, 蒋嫦月², 许超艳¹, 蒙夏艳¹, 李志峰¹, 黄献珍¹, 朱庆东¹, 付亮³, 陆普选³, 谢周华¹

1.南宁市第四人民医院/广西艾滋病临床治疗中心（南宁）结核病科 ,广西南宁 530000;
2.南宁市第四人民医院/广西艾滋病临床治疗中心（南宁）药学部,广西南宁 530000;
3.深圳市第三人民医院/南方科技大学第二附属医院肺病医学部,国家感染性疾病临床医学研究中心（深圳）,广东省感染性疾病（结核病）临床研究中心,深圳市结核病临床研究中心,广东深圳 518112

收稿日期:2025-11-28 出版日期:2025-12-31 发布日期:2026-01-26
通讯作者: 谢周华,Email：1491348066@qq.com
基金资助:
广西重点研发计划项目（桂科AB25069097）

WHO 2025 global tuberculosis report 2025 key data analysis for the world and China

He Huawei¹, Huang Aichun¹, Li Wei¹, Jiang Changyue², Xu Chaoyan¹, Meng Xiayan¹, Li Zhifeng¹, Huang Xianzhen¹, Zhu Qingdong¹, Fu Liang³, Lu Puxuan³, Xie Zhouhua¹

1. Department of Tuberculosis, The Fourth People's Hospital of Nanning, the Clinical Treatment Center for AIDS of Guangxi(Nanning), Guangxi Nanning 530000, China;
2. Department of Pharmacy, The Fourth People's Hospital of Nanning, the Clinical Treatment Center for AIDS of Guangxi(Nanning), Guangxi Nanning 530000, China;
3. Department of Pulmonary Medicine, Shenzhen Third People's Hospital, Southern University of Science and Technology, National Clinical Research Center for Infectious Disease (Shenzhen), Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Clinical Research Center for Tuberculosis, Guangdong Shenzhen 518112, China

Received:2025-11-28 Online:2025-12-31 Published:2026-01-26

摘要/Abstract

摘要： WHO 2025年全球结核病报告显示,2024年全球估算新增结核病患者1070万例,中国新增病例数约占全球发病数的6.5%,在30个结核病高负担国家中位列第4。全球结核病死亡人数约123万例,中国在死亡率控制方面取得显著进展。2024年,全球约有39万例耐多药/利福平耐药结核病患者;其中,中国约有2.77万例。2015–2024年结核病发病率累计下降12%,死亡人数净减少29%,但仍有约47%的结核病患者及其家庭面临灾难性支出,与WHO“终止结核病策略”中所确定的阶段性目标:“到2025年结核病发病率较2015年降低50%、死亡率降低75%”存在较大差距。2024年全球新诊断并报告结核病患者830万例,为WHO监测全球结核病数据以来的最高值,较估算数少约240万例,反映出病例发现与报告环节仍面临挑战。尽管COVID-19大流行后全球结核病诊断治疗服务呈现复苏趋势,但仍面临国际援助资金削减等新挑战。WHO呼吁各国进一步增加结核病的投入,推动预防性治疗和创新工具推广应用。参考全球数据,中国在扩大快速诊断技术的覆盖率和预防性治疗范围等方面已取得突破性进展,但耐药结核病监控和医疗支出的有效控制仍需加强。为实现“2035年终结结核病”的战略目标,未来需要多部门深化协同,形成长效治理合力,共同推进结核病防控工作的系统化、可持续化发展。

关键词: 结核病, 报告, 终结结核病策略, 疾病负担, 世界卫生组织

Abstract: The WHO Global Tuberculosis Report 2025 shows that there were 10.7 million new tuberculosis(TB) cases globally in 2024, with China accounting for approximately 6.5% of global incidence, ranking 4th among the 30 high TB burden countries. Global TB deaths totaled approximately 1.23 million, with China making significant progress in mortality control. In 2024, there were approximately 390 000 cases of multidrug-resistant/rifampicin-resistant TB globally; of these, China had about 27 700 cases. From 2015 to 2024, TB incidence cumulatively decreased by 12%, and deaths decreased by 29%, but approximately 47% of TB patients and their families still face catastrophic expenditures. This falls significantly short of the World Health Organization End TB Strategy milestone targets of "reducing TB incidence by 50% and mortality by 75% by 2025 compared to 2015." In 2024, 8.3 million TB patients were newly diagnosed and reported globally, the highest number since WHO began monitoring global TB data, but approximately 2.4 million fewer than estimated, reflecting challenges in case detection and reporting. Although global TB diagnostic and treatment services show recovery trends after the COVID-19 pandemic, new challenges such as reduced international aid funding remain. World Health Organization calls on countries to further increase investment in TB, promote preventive treatment, and expand the application of innovative tools. Based on global data, China has made breakthrough progress in improving coverage of rapid diagnostic technologies and expanding preventive treatment, but monitoring of drug-resistant TB and effective control of medical expenditures still need strengthening. To achieve the strategic goal of "ending TB by 2035," future efforts require deepened collaborative cooperation among multiple sectors including health, education, justice, social security, and civil affairs to form long-term governance synergy and jointly promote systematic and sustainable development of TB prevention and control.

Key words: Tuberculosis, Report, End Tuberculosis Strategy, Burden of disease, World Health Organization

中图分类号:

R521
R563

何华伟, 黄爱春, 李纬, 蒋嫦月, 许超艳, 蒙夏艳, 李志峰, 黄献珍, 朱庆东, 付亮, 陆普选, 谢周华. WHO 2025年全球结核病报告：全球与中国关键数据分析[J]. 新发传染病电子杂志, 2025, 10(6): 1-9.

He Huawei, Huang Aichun, Li Wei, Jiang Changyue, Xu Chaoyan, Meng Xiayan, Li Zhifeng, Huang Xianzhen, Zhu Qingdong, Fu Liang, Lu Puxuan, Xie Zhouhua. WHO 2025 global tuberculosis report 2025 key data analysis for the world and China[J]. Electronic Journal of Emerging Infectious Diseases, 2025, 10(6): 1-9.

参考文献

[1] WORLD HEALTH ORGANIZATION. Global tuberculosis report2025[EB/OL].[2025-11-12]. https://www.who.int/publications/i/item/9789240116924.
[2] CHURCHYARD G, KIM P, SHAH NS, et al.What We Know About Tuberculosis Transmission: An Overview[J]. Infect Dis, 2017, 216(suppl_6):S629-S635.
[3] BAGCCHI S.WHO's Global Tuberculosis Report 2022[J]. Lancet Microbe, 2023, 4(1):e20.
[4] 卢春容, 谭卫国, 陆普选, 等. 2023年WHO全球结核病报告:全球与中国关键数据分析[J/CD].新发传染病电子杂志, 2023, 8(6): 73-78.
[5] KANT S, TYAGI R.The impact of COVID-19 on tuberculosis: challenges and opportunities[J]. Ther Adv Infect Dis, 2021, 8:20499361211016973.
[6] MAO X, WANG J, XU J, et al. Current diagnosing strategies for Mycobacterium tuberculosis and its drug resistance: a review[J]. Appl Microbiol, 2025, 136(5):lxaf100.
[7] REID M, ROBERTS G, GOOSBY E, et al.Monitoring Universal Health Coverage (UHC) in high Tuberculosis burden countries: Tuberculosis mortality an important tracer of UHC service coverage[J]. PLoS One, 2019, 14(10):e0223559.
[8] 余卫业, 谭卫国, 罗一婷, 等. 2018WHO全球结核报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2018, 3(4): 228-233.
[9] 任坦坦, 陆普选, 邓国防, 等. 2020 WHO全球结核报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2020, 5(4): 280-284.
[10] 卢春容, 房宏霞, 陆普选, 等. WHO 2021年全球结核病报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2021, 6(4): 368-372.
[11] 宋敏, 陆普选, 方伟军, 等. 2022年WHO全球结核病报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2023, 8(1): 87-92.
[12] JEON SM, KIM TH, LEE S, et al.Research and International Cooperation for Shortening the Treatment Duration of Tuberculosis[J]. Jugan Geongang Gwa Jilbyeong, 2025, 18(11 Suppl):102-118.
[13] SHIN E, KIM SM, YUN JS, et al. Status of Tuberculosis Vaccines Development in Clinical Trials[J]. Jugan Geongang Gwa Jilbyeong, 2025, 18(11 Suppl):88-101. Korean.
[14] ALBERTO NR, ALBERTO IRI, AGRIPO IK, et al.Policy analysis on drug-resistant tuberculosis in ASEAN member countries using a governance framework approach: a scoping review[J]. BMJ Glob Health, 2025, 10(11):e016346.
[15] MUHIE NS. Incidence Rate, Survival Rate,Predictors for Virological Failure Among Adult TB/HIV Coinfected Clients[J]. Trop Med, 2025, 2025:2011556.
[16] LI J, WU W, FANG Z, et al.Diagnostic assistance method for RR-TB/MDR-TB patients under treatment based on CNN-LSTM[J]. Sci Rep, 2025, 15(1):38035.
[17] WORLD HEALTH ORGANIZATION.The second United Nations high-level meeting on TB: new global pledge to end the TB epidemic[EB/OL].[2023-11-10].https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/featured-topics/un-declaration-on-tb.
[18] AN Y, NI R, ZHUANG L, et al.Tuberculosis vaccines and therapeutic drug: challenges and future directions[J]. Mol Biomed, 2025, 6(1):4.
[19] TAIT DR, HATHERILL M, VAN DER MEEREN O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis[J]. N Engl J Med, 2019, 381(25):2429-2439.
[20] ISKANDAR D, SUWANTIKA AA, PRADIPTA IS, et al.Clinical and economic burden of drug-susceptible tuberculosis in Indonesia[J]. Lancet Glob Health, 2023, 11(1):e117-e125.

WHO 2025年全球结核病报告：全球与中国关键数据分析

WHO 2025 global tuberculosis report 2025 key data analysis for the world and China

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	付亮, 邓国防, 卢水华. 2014—2024年全球结核病流行趋势与“终止结核病策略”进展：基于WHO全球结核病报告的纵向分析[J]. 新发传染病电子杂志, 2025, 10(6): 10-15.
[2]	吴迪, 刘志辉, 杨佳诺, 陈亮. 《WHO结核病整合指南模块4：治疗与关怀》的实践溯源与应用思考[J]. 新发传染病电子杂志, 2025, 10(6): 16-23.
[3]	詹梅, 赵颂涛, 郭建琼, 李同心, 杨松. 《WHO无症状结核病咨询报告》解读[J]. 新发传染病电子杂志, 2025, 10(5): 100-104.
[4]	何明杰, 许荣, 邓国防. 利福布汀在结核病共病中的应用进展[J]. 新发传染病电子杂志, 2025, 10(4): 76-82.
[5]	宋树林, 金观桥. 宿主转录组学、影像组学、影像基因组学在耐药结核病诊治中的应用[J]. 新发传染病电子杂志, 2025, 10(4): 83-88.
[6]	刘瑞花, 金慧芳, 王爱霞, 郑伟, 刘哲芳, 陈琛, 宋雪飞, 乌力吉, 王芙蓉. 《WHO结核病综合指南模块3——诊断》解读[J]. 新发传染病电子杂志, 2025, 10(4): 94-104.
[7]	黄嘉敏, 柯学, 李国保, 卢水华. 《WHO结核病整合指南模块1：预防——结核病预防性治疗（第二版）》解读[J]. 新发传染病电子杂志, 2025, 10(3): 92-98.
[8]	李成坤, 王锦华, 刘志东, 陈浩, 何楚文, 李晓芬, 陈文杰, 林艳伟. 基于数字技术结核病防控管理的卫生经济学评价[J]. 新发传染病电子杂志, 2025, 10(2): 63-69.
[9]	张英娈, 温莹, 熊华威, 万佳, 李媛, 高世同, 唐秀娟, 路滟, 陈志高, 孔东锋, 吕秋莹, 张振. 深圳市2004—2022年传染病类突发公共卫生事件风险监测与早期预警研究——基于两管理系统报告数据分析[J]. 新发传染病电子杂志, 2025, 10(1): 1-7.
[10]	乌力吉, 梁瑞云, 辛东益, 鲍晓慧, 何关执, 郑广平, 方伟军, 贺燕林. 免疫功能正常肝结核患者临床影像特征分析[J]. 新发传染病电子杂志, 2025, 10(1): 44-49.
[11]	李媛媛, 谢晶晶, 李树涛, 苏东栋, 郑甜, 陆普选, 彭溢. 2024年WHO全球结核病报告：全球与中国关键数据分析[J]. 新发传染病电子杂志, 2024, 9(6): 92-97.
[12]	段晓菲, 吴桂辉, 杨洁, 蒋良双. 2012–2022年成都市肺结核流行特征与治疗转归分析[J]. 新发传染病电子杂志, 2024, 9(5): 19-24.
[13]	朱庆东, 王琦, 宋畅, 赵春艳, 阳世雄. 高通量测序技术在结核病诊断和耐药检测中的应用进展[J]. 新发传染病电子杂志, 2024, 9(5): 78-82.
[14]	刘钰, 孙小琴, 刘婷, 徐亚丽, 虎维东. 肺部、肠道菌群与结核病发生发展的研究进展[J]. 新发传染病电子杂志, 2024, 9(4): 61-67.
[15]	王晓霞, 谭守勇, 黄绍梅, 胡海霞. 80例儿童中枢神经系统结核病临床特征分析[J]. 新发传染病电子杂志, 2024, 9(1): 37-41.